

Environmental and Social Data Sheet

Overview

Project Name:	PHARMACEUTICALS RDI PROGRAMME
Project Number:	2020-0571
Country:	Poland
Project Description:	The project supports the Promoter's R&D investments in several therapeutic areas, including cardio, diabetes, ophthalmic and respiratory diseases, over the period 2021-2023.
EIA required:	no
Project included in Carbon Footprint Exercise:	no

Environmental and Social Assessment

Environmental Assessment

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project does not fall under the scope of the EIA Directive 2014/52/EU amending Directive 2011/92/EU.

The Promoter maintains adequate internal procedures and management practices that are in line with best industry standards (e.g., GMP, FDA, etc.) and are subjected to audits.

Other Environmental and Social Aspects

If successful, the project is expected to lead to important social benefits, considering the targeted indications and their prevalence within the European population.

Through the R&D activities and investments, the Promoter is also expected to sustain its current level of skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

Considering the above, the project is deemed acceptable for the Bank's financing under environmental and social terms.